Prostate Cancer - Results from #23080

Systemic therapy in men with metastatic castration-resistant prostate cancer: A systematic review - Abstract May 29, 2013

Perineural invasion and TRUS findings are complementary in predicting prostate cancer biology - Abstract May 29, 2013

Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy - Abstract May 29, 2013

PET imaging in prostate cancer: Focus on prostate-specific membrane antigen - Abstract May 29, 2013

Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer - Abstract May 29, 2013

Pain questionnaire performance in advanced prostate cancer: Comparative results from two international clinical trials - Abstract May 29, 2013

Advancing precision medicine for prostate cancer through genomics - Abstract May 29, 2013

The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses - Abstract May 29, 2013

Researchers identify novel class of drugs for prostate cancers May 28, 2013

Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer - Abstract May 28, 2013

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide - Abstract May 28, 2013

Radiation therapy modalities in prostate cancer - Abstract May 28, 2013

Bone metastases and bone loss medical treatment in prostate cancer patients - Abstract May 28, 2013

Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol - Abstract May 28, 2013

Focal ablation of prostate cancer: Four roles for magnetic resonance imaging guidance - Abstract May 28, 2013

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) - Abstract May 28, 2013

Trends and estimates in prostate cancer incidence, mortality and prevalence in the Slovak Republic, 1968-2012 - Abstract May 28, 2013

Metabolic and toxicological considerations of newly approved prostate cancer drugs - Abstract May 28, 2013

Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone - Abstract May 28, 2013

Prostate-specific antigen bounce after high-dose-rate monotherapy for prostate cancer - Abstract May 27, 2013

Page 1155 of 1435